Últimas noticias sobre Immunome (NASDAQ:IMNM) Bolsa

Immunome

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.

Immunome Inc

Telsey Advisory Group analyst Dana Telsey maintains Stitch Fix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) with a Market Perform and maintains $6 price target.

News

Price Target

Analyst Ratings

SFIX

Telsey Advisory Group Maintains Market Perform on Stitch Fix, Maintains $6 Price Target

Guidance

ARCO

Arcos Dorados Reaffirms 2025 Guidance With 90-100 Restaurant Openings And Capital Expenditures Of $300M-$350M

Arcos Dorados Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.21 by 33.33 percent. This is a 7.69 percent increase over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $1.144 billion which missed the analyst consensus estimate of $1.152 billion by 0.71 percent. This is a 2.72 percent decrease over sales of $1.176 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

Arcos Dorados Holdings Q4 2024 GAAP EPS $0.28 Beats $0.21 Estimate, Sales $1.144B Miss $1.152B Estimate

Needham analyst Gil Blum reiterates Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) with a Buy and maintains $5 price target.

Reiteration

GERN

Needham Reiterates Buy on Geron, Maintains $5 Price Target

Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) disclosed a collaboration with Singapore Airlines (SIA) to enhance <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44266464/singapore-airlines-and-salesforce-collaborate-on-ai-powered-customer-servicing-applications-plan-t" rel="noreferrer noopener">the customer case management system</a>.
As per the deal, SIA will implement Agentforce, an AI-powered system that automates specific tasks to streamline customer service operations.
Additionally, both companies will work together at Salesforce&#8217;s AI Research hub in Singapore to develop AI-driven solutions for the aviation industry, bringing added value and benefits to airlines.
Powered by Salesforce&#8217;s Data Cloud, which consolidates relevant data, Agentforce enhances AI-driven support by providing tailored recommendations and solutions.
Additionally, SIA will leverage Einstein&#8217;s generative AI within Service Cloud to summarize past customer interactions and offer guidance on assistance.
This will help representatives anticipate needs, customize responses, and reduce response times, enabling more efficient and proactive customer service.
Marc Benioff, Chair and CEO, Salesforce stated, &#8220;We&#8217;re thrilled to partner with Singapore Airlines, a trailblazer in this AI revolution, to elevate their already outstanding customer service to unprecedented heights, augment their employees and collaborate on groundbreaking AI solutions for the airline industry.&#8221;
Goh Choon Phong, Chief Executive Officer, Singapore Airlines, said, &#8220;Integrating Agentforce, Einstein in Service Cloud, and Data Cloud into SIA&#8217;s customer case management system enhances our ability to efficiently assist our customers, and marks the first step in our collaboration. Together, we will co-create AI solutions that drive meaningful and impactful change and set new standards for service excellence in the airline industry.&#8221;
Last week, Salesforce&nbsp;introduced Agentforce 2dx, which is the latest version of its digital labor platform designed to integrate autonomous&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44146057/salesforce-unveils-agentforce-2dx-ai-agents-that-work-beyond-chatbots" rel="noreferrer noopener">AI agents into business operations</a>.
Investors can gain exposure to the stock via&nbsp;iShares Expanded Tech-Software Sector ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/IGV#BATS">IGV</a>) and&nbsp;REX FANG &amp; Innovation Equity Premium Income ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEPI#NASDAQ">FEPI</a>).
Price Action: CRM shares are up 0.96% at $279.70 premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44200350/salesforce-ai-expansion-sparks-analyst-optimism-400-price-forecast-set" target="_blank" rel="noreferrer noopener">Salesforce Is Trading Below 200-DMA, But Goldman Sachs Sees Huge Stock Upside After Agentforce 2dx Unveil</a></li>
</ul>
Photo: Photo Gonzo via Shutterstock.

Equities

Large Cap

Contracts

FEPI

AI Takes Flight: Singapore Airlines Taps Salesforce For Next-Gen Customer Service Tech

General

IRBT

iRobot's Board Of Directors Initiate A Formal Strategic Review To Evaluate Options Including Debt Refinancing And Potential Sale

Rosenblatt analyst Chris Brendler maintains Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Buy and maintains $305 price target.

COIN

Rosenblatt Maintains Buy on Coinbase Global, Maintains $305 Price Target

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) with a Buy and maintains $7 price target.

ATOS

HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $7 Price Target

Upstream Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>) reported quarterly sales of $613.00 thousand which missed the analyst consensus estimate of $686.67 thousand by 10.73 percent. This is a 0.99 percent increase over sales of $607.00 thousand the same period last year.

Upstream Bio Q3 Sales $613.00K Miss $686.67K Estimate

NVGS

Navigator Holdings Q4 2024 Adj. EPS $0.38, Sales $144.031M Beat $135.581M Estimate

WIIM

BURU

Nuburu shares are trading higher after the company said it believes its retained intellectual property,  personnel and relationships will allow it to continue operating in the laser technology field, with a focus on defense, semiconductor and industrial manufacturing applications.

SNCR

Synchronoss Technologies shares are trading higher after the company reported better-than-expected Q4 earnings and sales.

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) from Neutral to Neutral.

AGEN

HC Wainwright & Co. Reiterates Neutral on Agenusto Neutral

Rosenblatt analyst Mike Genovese maintains Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) with a Neutral and lowers the price target from $79 to $73.

CIEN

Rosenblatt Maintains Neutral on Ciena, Lowers Price Target to $73

iRobot shares are trading lower after the company disclosed substantial doubt about its ability to continue as a going concern.

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) from Neutral to Neutral.

HC Wainwright & Co. Reiterates Neutral on Geronto Neutral

Heinz Launched Dip For Potato Chips, Same Unmistakable Ketchup, New Way To Enjoy

Stitch Fix shares are trading higher following strong Q2 earnings and upbeat Q3 guidance.

GRPN

Groupon shares are trading higher after the company reported better-than-expected Q4 revenue results.

Needham analyst Ryan Koontz maintains Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) with a Buy and lowers the price target from $95 to $90.

Needham Maintains Buy on Ciena, Lowers Price Target to $90

Health Care

Press Releases

Hummingbird Bioscience Licenses Novel Antibodies to Immunome

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Immunome Announces Proposed Public Offering of Common Stock

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer

Comments

Immunome

Noticias

Últimas noticias sobre Immunome (NASDAQ:IMNM) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL